Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization

被引:11
作者
Bertolini, F
Lanza, A
Peccatori, F
Zibera, C
Gibelli, N
Perotti, C
Da Prada, GA
Torretta, L
Corocchio, E
Martinelli, G
della Cuna, GR
机构
[1] Pavia Med Ctr, IRCCS Maugeri Fdn, Div Med Oncol & Expt Med, I-27100 Pavia, Italy
[2] IRCCS San Matteo Hosp, Blood Transfus Unit, Pavia, Italy
[3] IRCCS European Inst Oncol, Div Med Oncol, Milan, Italy
关键词
breast cancer; G-CSF; mobilization; stem cells; transplantation;
D O I
10.1023/A:1008226428543
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We compared hematopoietic progenitor cell (HPC) collection and neoplastic cell contamination in breast cancer patients given cyclophosphamide (CTX) plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization. Patients and methods: In 57 stage II-III breast cancer patients, CD34+ cells, colony-forming units-granulocyte macrophage (CFU-GM), early HPC and breast cancer cells were counted in HPC collections obtained after CTX plus G-CSF (n = 27) or G-CSF-alone mobilization (n = 30). Results. The CD34+ cell collection was about two-fold greater after CTX plus G-CSF mobilization (11.0 +/- 7.9 vs. 5.8 +/- 3.5 x 10(6)/kg, P < 0.001). Similarly, the total number of CFU-GM, CD34+CD38- cells and of week-5 cobblestone area forming cells (CAFC) collected was significantly higher in patients mobilized with CTX plus G-CSF. Breast cancer cells were found in the apheresis products of 22% of patients mobilized with CTX plus G-CSF and in 10% of patients mobilized with G-CSF alone (P = 0.36). Of seven patients who failed G-CSF-alone mobilization and eventually underwent chemotherapy plus G-CSF mobilization, none had cytokeratin-positive cells after G-CSF mobilization, whereas four out of seven had cytokeratin-positive cells after chemotherapy plus G-CSF (P = 0.07 by chi(2) test). Conclusion: The CTX plus G-CSF mobilization protocol was associated with a significantly higher HPC collection. However, this benefit was not accompanied by a reduction in the incidence of tumor-contaminated HPC graft.
引用
收藏
页码:913 / 916
页数:4
相关论文
共 19 条
[1]   High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America [J].
Antman, KH ;
Rowlings, PA ;
Vaughan, WP ;
Pelz, CJ ;
Fay, JW ;
Fields, KK ;
Freytes, CO ;
Gale, RP ;
Hillner, BE ;
Holland, HK ;
Kennedy, MJ ;
Klein, JP ;
Lazarus, HM ;
McCarthy, PL ;
Saez, R ;
Spitzer, G ;
Stadtmauer, EA ;
Williams, SF ;
Wolff, S ;
Sobocinski, KA ;
Armitage, JO ;
Horowitz, MM .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) :1870-1879
[2]   Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation [J].
Bensinger, WI ;
Clift, R ;
Martin, P ;
Appelbaum, FR ;
Demirer, T ;
Gooley, T ;
Lilleby, K ;
Rowley, S ;
Sanders, J ;
Storb, R ;
Buckner, CD .
BLOOD, 1996, 88 (07) :2794-2800
[3]   Multilineage long-term engraftment potential of drug-resistant hematopoietic progenitors [J].
Bertolini, F ;
Battaglia, M ;
Lanza, A ;
Gibelli, N ;
Palermo, B ;
Pavesi, L ;
Caprotti, M ;
dellaCuna, GR .
BLOOD, 1997, 90 (08) :3027-3036
[4]   Individual stem cell quality in leukapheresis products is related to the number of mobilized stem cells [J].
Breems, DA ;
vanHennik, PB ;
Kusadasi, N ;
Boudewijn, A ;
Cornelissen, JJ ;
Sonneveld, P ;
Ploemacher, RE .
BLOOD, 1996, 87 (12) :5370-5378
[5]   GENE-MARKING TO TRACE ORIGIN OF RELAPSE AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].
BRENNER, MK ;
RILL, DR ;
MOEN, RC ;
KRANCE, RA ;
MIRRO, J ;
ANDERSON, WF ;
IHLE, JN .
LANCET, 1993, 341 (8837) :85-86
[6]   SENSITIVE DETECTION OF OCCULT BREAST-CANCER BY THE REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION [J].
DATTA, YH ;
ADAMS, PT ;
DROBYSKI, WR ;
ETHIER, SP ;
TERRY, VH ;
ROTH, MS .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (03) :475-482
[7]   Relationship of CD34(+) cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation [J].
Kiss, JE ;
Rybka, WB ;
Winkelstein, A ;
deMagalhaesSilverman, M ;
Lister, J ;
DAndrea, P ;
Ball, ED .
BONE MARROW TRANSPLANTATION, 1997, 19 (04) :303-310
[8]   CD34(+) cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies [J].
Mavroudis, D ;
Read, E ;
CottlerFox, M ;
Couriel, D ;
Molldrem, J ;
Carter, C ;
Yu, M ;
Dunbar, C ;
Barrett, J .
BLOOD, 1996, 88 (08) :3223-3229
[9]   Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow [J].
Ottinger, HD ;
Beelen, DW ;
Scheulen, B ;
Schaefer, UW ;
GrosseWilde, H .
BLOOD, 1996, 88 (07) :2775-2779
[10]  
Pantel K, 1994, J Hematother, V3, P315, DOI 10.1089/scd.1.1994.3.315